Dimitra Skondra, MD, PhD, discussed her talk on how the diet and gut microbiome can affect the development of age-related macular degeneration. Dimitra Skondra, MD, PhD, discussed her talk on how the ...

According to MingMed Biotechnology, 1 the QA102-CS201 trial enrolled 150 patients with intermediate atrophic AMD and randomly ...

MingMed Biotechnology Co., Ltd, a biomedical firm focused on the discovery and development of novel therapeutics across multiple therapeutic areas, announced positive results from its Phase II ...

MingMed Biotechnology Co., Ltd, a biomedical firm focused on the discovery and development of novel therapeutics across multiple therapeutic areas ...

The Norman Public Schools Board of Education approved the purchase of land for a new farm, heard proposed changes to a board ...

Sanaregen Vision Therapeutics, a clinical-stage regenerative medicine company, today announced clearance by the U.S. Food and Drug Administration to conduct a Phase I/II clinical trial for SVT-001, ...

Age is a major risk factor for geographic atrophy (GA). As the eyes age, natural defenses weaken, blood flow may decline, and waste removal may slow, allowing deposits called drusen to build up.

A study funded in part by the National Institutes of Health (NIH) has revealed important insights into the genetics of deposits in the eye, known as reticular pseudodrusen (RPD), that are linked to ...

Retinal drusen are yellow/white-colored spots seen under the retina of your eye that are made up of proteins and a type of fat called lipids. The retina is the layer of cells lining the inside surface ...

We reviewed the evidence about the effect of laser treatment of the centre of the retina in people with macular drusen to prevent the occurrence of the more advanced type of age-related macular ...

What Is Optic Nerve Drusen? Optic nerve drusen is a rare eye condition that affects between 3 and 24 people out of every 1,000 in the population. It’s difficult to estimate exactly how common this ...

The FDA announced marketing authorization of a form of light therapy as the first-ever treatment for dry age-related macular degeneration (AMD). LumiThera's Valeda Light Delivery System generates ...